Sales up 6.4%*, excluding H1N1 impact
Improvement in operating margin: +13%**
Major strategic and operational advances
The Board of Directors of bioMérieux, a world leader in the field of in vitro diagnostics, met today and approved the consolidated financial statements for the year ended December 31, 2010. The meeting was chaired by Jean-Luc Bélingard and attended by the Statutory Auditors. The financial statements have been audited and the Statutory Auditors will be issuing an unqualified opinion in the coming days.
Download
- Filename
- PR_bioMerieux_RESULTATS_2010_EN2.pdf
- Size
- 110 KB
- Format
- application/pdf